Haleon plc (HLN) Q2 2026 Earnings Call Prepared Remarks Transcript

Haleon reported H1 2026 organic revenue up 2.6%, improving in Q2 with organic revenue up 3.1% despite a challenging consumer and macro environment. In the first half, volume/mix contributed 1.4%, 73% of the portfolio gained or maintained market share, and productivity delivered 140bps of constant-currency gross margin expansion alongside 8.2% adjusted operating profit growth. Cash generation remains strong with continued investment to drive future growth, while North America showed improving execution and early signs of underlying market improvement.

Analysis

HLN is emerging as a margin-repair compounder rather than a pure top-line story. The key market mechanism is that productivity-led gross margin expansion can keep EPS growing faster than revenue even in a slow consumer backdrop, which should support multiple stability versus lower-quality staples with more price-led growth. The competitive implication is most acute in oral care and OTC where execution improvements can translate into shelf-share gains; the likely losers are share-fragile peers such as Kenvue and, to a lesser extent, Colgate if HLN’s improved execution persists through the next planogram cycle.

The near-term risk is that investors extrapolate the current share gains into a straight-line re-acceleration. Europe remains the main falsifier: if that region stays negative, the market may treat the earnings beat as transient and cap rerating. Over the next 1-3 months, the catalyst is consensus revisions around margin rather than sales; if gross margin improvement continues at anything near current pace, FY earnings estimates should move up before revenue estimates do. Over 6-18 months, sustained EM strength would matter more than North America because it changes the narrative from defensive staple to global branded consumer growth.

Contrarian view: the stock may still be under-owned for a business with improving execution and visible self-help, especially if the market is over-discounting mature-category stagnation. The better setup is not a chase on the print, but a gradual long built on evidence that productivity gains are durable and share gains are broadening. Falsifier: a reversal in volume/mix or gross margin progress in the next two quarters, or a guidance tone that implies Europe weakness is spreading into other regions.

Key Decisions for Investors

• Add HLN on 1-3 month weakness, targeting a rerating as margin revisions outpace revenue revisions; use a trailing stop if organic growth slips below ~2% or gross margin expansion meaningfully decelerates.
• Pair trade: long HLN / short KVUE for 1-3 months if you want to express relative execution improvement in consumer health; the trade works if HLN keeps taking share while KVUE remains more exposed to softer US OTC demand.
• Relative-value watch: long HLN vs short CL only on confirmation that oral-care share gains persist into the next quarter; the risk/reward is better if channel checks show HLN gaining shelf space rather than just benefiting from temporary promo activity.
• If you want low-conviction exposure, own HLN through XLP rather than outright until Europe stabilizes; that reduces single-name downside while keeping upside to earnings revision flow.